Affibody is a clinical-stage Swedish biotech company focused on developing next-generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody® molecules are small, robust, and easily manufactured proteins that can be designed to bind with high affinity and specificity to a wide variety of target proteins. This technology is applied to develop innovative drugs for autoimmune diseases, oncology, and other conditions with unmet medical needs. The company aims to create differentiated therapeutics that can significantly improve patients' lives.
The headquarters serves as the central hub for Affibody's research and development, clinical operations, business development, and corporate administration.
Modern laboratory and office spaces designed for advanced biopharmaceutical research, protein engineering, drug development, and collaborative work, situated within a leading Scandinavian life science cluster.
Affibody fosters a dynamic, science-driven, and collaborative work environment. The culture encourages innovation, teamwork among multidisciplinary experts, and a strong commitment to scientific rigor in developing novel therapies.
The Solna headquarters is critical to Affibody's entire value chain, from initial drug discovery and protein engineering to preclinical and clinical development, and strategic partnership management. Its location provides access to talent and research collaborations.
Affibody AB supports its global reach primarily through strategic collaborations and licensing partnerships with international pharmaceutical and biotech companies for the co-development and commercialization of its therapeutic programs. While its core operations are centralized in Sweden, its clinical trials often involve sites across multiple countries, and its business development activities are global in scope, targeting worldwide markets for its innovative therapies.
Gunnar Asplunds Allé 24
Solna
Stockholm County
Sweden
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Affibody AB' leadership includes:
Affibody AB has been backed by several prominent investors over the years, including:
In the last 12 months (from May 2023 to May 2024), Affibody AB strengthened its executive team with the appointment of a new Chief Financial Officer. No major executive departures have been publicly announced during this specific period.
Discover the tools Affibody AB uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Affibody AB likely follows common corporate email formatting conventions. A frequently observed pattern for companies of its size and nature is using the employee's first name and last name, or an initial combined with the last name.
firstname.lastname@affibody.com
Format
anders.svensson@affibody.com
Example
80%
Success rate
Affibody Website • January 24, 2024
Affibody AB announced that the first patient has been dosed in a pivotal Phase 2 trial evaluating izokibep (ABY-035) for the treatment of hidradenitis suppurativa (HS), a chronic and debilitating skin condition....more
Affibody Website • December 20, 2023
Affibody's partner, Inmagene Biopharmaceuticals, received clearance from China's Center for Drug Evaluation (CDE) to initiate a registrational trial for izokibep in patients with ankylosing spondylitis....more
Affibody Website • October 2, 2023
Affibody AB announced the appointment of Jens Jacobsson as its new Chief Financial Officer (CFO), effective November 1, 2023. He brings extensive experience from leading finance functions in various industries....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Affibody AB, are just a search away.